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S U M M A R Y
Objectives: Intense migration to the United Arab Emirates from tuberculosis (TB) high-endemic areas
presents a particular risk to the population. Screening for latent tuberculosis infection (LTBI) usually
involves risk assessment, the tuberculin skin test (TST), and interferon-gamma release assay (IGRA). This
study investigated the use of an IGRA to screen for LTBI and compared its performance with a risk
assessment questionnaire.
Methods: This prospective cross-sectional study was conducted at seven Ambulatory Healthcare
Services facilities in Abu Dhabi. Participants (88% Emiratis) were pediatric patients presenting for routine
care. The QuantiFERON-TB Gold In-Tube test was performed and the parents completed a questionnaire
assessing TB risk factors.
Results: Six-hundred and ninety-nine subjects (median age 8.7 years, interquartile range 9.2 years) were
enrolled; 669 (96%) agreed to testing. Four patients had a positive IGRA; one had previously been treated
for TB, resulting in three patients with LTBI. The estimated LTBI prevalence was 0.45% (95% conﬁdence
interval 0.09–1.3). A household contact from a TB high-endemic area was reported in 44%, travel to a TB
high-endemic area in 10%, and contact with someone with a chronic cough in 7%, a TB case in 3%, a TST-
positive case in 2%, and an IGRA-positive case in 2%. Fifty percent of participants had at least one risk
factor. The risk assessment did not predict a positive IGRA.
Conclusions: The questionnaire yielded a risk of TB exposure of 50%, however the LTBI prevalence, as
deﬁned by the IGRA, was low (0.45%).
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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The United Arab Emirates (UAE) is considered a tuberculosis
(TB) low-endemic country, with a TB disease prevalence of 2.4 per
100 000 population.1 Increased travel from TB high-endemic areas,
however, presents a particular risk to the population. In a recent
study, the prevalence of pulmonary TB in the visa screening
program was 39 per 100 000.2 The infection was more common in
nursery workers, housemaids, and private drivers.2 The prevalence
of latent tuberculosis infection (LTBI; positive QuantiFERON-TB* Corresponding author. Tel.: +971 3 713 7411; fax: +971 3 767 2022.
E-mail address: alsuwaidia@uaeu.ac.ae (A.R. Alsuwaidi).
http://dx.doi.org/10.1016/j.ijid.2013.12.020
1201-9712  2014 The Authors. Published by Elsevier Ltd on behalf of International Soassay) in Emirati medical students, on the other hand, was found to
be 8%.3 Thus, the UAE population (especially children) is at high
risk of TB exposure, perhaps stressing the need for universal
screening using the tuberculin skin test (TST) or an interferon-
gamma release assay (IGRA).4,5
Approximately a third of individuals exposed to TB are expected
to develop LTBI, and each case has a life-long risk of progressing to
TB.6 Treatment with isoniazid reduces this risk by at least 75%.7
Thus, untreated LTBI constitutes a signiﬁcant epidemic reservoir.
The propensity to develop TB disease is much higher in young
children.8 Therefore, effective pediatric screening is vital.
The TST is the standard method for determining TB exposure
(immune response to Mycobacterium tuberculosis). In the UAE, the
bacillus Calmette–Gue´rin (BCG) vaccine is administered to allciety for Infectious Diseases. Open access under CC BY-NC-SA license.
Table 1
LTBI in the studied pediatric populationa
Total
participants
Participants with IGRA LTBI prevalenceb
Overall 699 (100%) 669 (96%) 3 (0.45%)
Gender
Male 322 (46%) 305 (43%) 1 (0.33%)
Female 377 (54%) 364 (52%) 2 (0.55%)
Nationality
Emirati 617 (88%) 592 (91%) 3 (0.51%)
Non-Emirati 65 (9%) 60 (91%) 0 (0%)
Unknown 17 (2%) 17 (0%) 0 (0%)
LTBI, latent tuberculosis infection; IGRA, interferon-gamma release assay.
a Results are expressed as n (%).
b LTBI prevalence was set as the number of LTBI cases/participants with IGRA
results. LTBI was deﬁned as a positive IGRA in a child without prior TB disease and
with normal clinical assessment and chest X-ray. Four patients had a positive IGRA;
one of these patients had previously been treated for TB disease.
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TST (10 mm induration attributable to BCG) was 8.5% within the
ﬁrst 10 years of BCG administration and 1% thereafter.9 The
prevalence of a false-positive TST from non-tuberculous myco-
bacteria is also signiﬁcant, ranging from 0.1% to 2.3%.9 These false-
positive TST reactions discourage physicians and families from
accepting treatment and also result in the treatment of some
children who are not infected.
The IGRA is based on the release of interferon-gamma (IFN-g)
by T-lymphocytes in response to the M. tuberculosis antigens ESAT-
6, CFP-10, and TB7.7(p4), which are lacking in BCG vaccines and
most non-tuberculous mycobacteria. The higher speciﬁcity of the
IGRA may permit its use in identifying patients likely to beneﬁt
from TB therapy.10,11 This assay, however, has signiﬁcant limita-
tions, including a within-subject inter-laboratory variability of
about 6%.12–14
This study investigated the use of an IGRA to screen for LTBI in
pediatric patients from the eastern region of Abu Dhabi. The use of




This prospective cross-sectional study was conducted at seven
Ambulatory Healthcare Services (AHS) centers in the eastern
region of the Emirate of Abu Dhabi (UAE). These facilities serve
mostly urban populations. From April 29 to October 31, 2013,
patients aged 1–19 years presenting for routine care were
recruited randomly. The study was approved by the Institutional
Review Board of the College of Medicine and Health Sciences
(CMHS), UAE University (Protocol #13/14). Written informed
consent was obtained for each participant. For the young and those
unable to read, consent was obtained from the parents.
2.2. Data collection
Demographic data were collected. The parents completed a
modiﬁed risk assessment questionnaire (developed by the
Pediatric Tuberculosis Collaborative Group and American Thoracic
Society4) (Table S1, Supplementary Material). The questionnaire
was administered face-to-face by a trained nurse. The questions
were given in the primary language of the families, via an
interpreter when necessary.
The QuantiFERON-TB Gold In-Tube test (Cellestis Limited,
Carnegie, Victoria, Australia) was performed on enrolled partici-
pants who consented to the test. The assay was performed as per
the manufacturer’s instructions. The QuantiFERON-TB Gold
collection tubes were validated for volumes of 0.8–1.2 ml (black
marks on the side of tubes indicate 1-ml ﬁll volume). Brieﬂy,
approximately 1 ml of blood was collected by venipuncture
directly into each of the following tubes: (1) heparin (nil), (2)
heparin + dextrose + phytohemagglutinin A (mitogen), and (3)
heparin + dextrose + TB antigens (ESAT-6, CFP-10, and TB7.7(p4)).
Tubes were shaken vigorously (10 times) to ensure the entire inner
surface had been coated with the blood. The samples were
transferred to an incubator set at 37 8C within 8 h of collection and
incubated for 16–24 h. The tubes were then centrifuged at 25 8C
and approximately 3000 g for 15 min. The plasma was stored at
2 8C for <4 weeks. Plasma IFN-g was determined by ELISA using
the reagents supplied. The results were interpreted as per the
manufacturer’s instructions (Table S2, Supplementary Material).
Children with a negative QuantiFERON-TB Gold In-Tube test
result were not evaluated further. Children with a positive test
result underwent a clinical assessment, the TST (using theMantoux technique), and a chest X-ray. For the purpose of this
study, LTBI was deﬁned as a positive IGRA in a child without prior
TB disease and with a normal clinical assessment and chest X-ray.
These children were offered standard LTBI treatment.
2.3. Statistical analysis
With a reported prevalence of positive TST of 10% in UAE
children15 and a similar prevalence of positive IGRA in healthy
medical students of the College of Medicine and Health Sciences
(UAE University),3 a sample size of 553 subjects was estimated to
give study precision of 2.5% with 95% conﬁdence levels (OpenEpi,
version 2; open source calculator: http://www.openepi.com). With
an estimated 30% of participants expected to have either
incomplete data or to refuse blood sampling, the required sample
size was increased to 699. The primary outcome was estimating
the prevalence of LTBI. The secondary outcomes were assessing TB
risk factors in the questionnaire and correlating them with the
IGRA results. The dependent variable or outcome was IGRA results.
The prevalence of LTBI was calculated with 95% conﬁdence
intervals (95% CI). The independent variables included ethnicity,
age, gender, and risk of TB exposure. Univariate analysis of the risk
factors associated with a positive IGRA included non-parametric
tests, such as Kruskal–Wallis one-way analysis of variance for
independent data (as data did not follow a normal distribution).
Proportions were compared with the Chi-square test or Fisher’s
exact test (if numbers were small). The analyses were performed
using SPSS 15.0 (SPSS Inc., Chicago, IL, USA) and the statistical
signiﬁcance was deﬁned by a two-tailed p-value of <0.05.
3. Results
Six-hundred and ninety-nine participants were enrolled in the
study and completed the questionnaire. Their median age was 8.7
years (interquartile range 9.2 years). The age distribution was: <1
year, 5 (0.7%); 1–2 years, 41 (5.9%); 2–5 years, 143 (20.5%); 5–10
years, 198 (28.3%); 10–15 years, 168 (24.0%); and >15 years, 144
(20.6%). There were 322 males (46%) and 617 (88%) Emiratis
(Table 1).
Only 669 (96%) participants agreed to blood sampling. The
remaining 30 (4%) did not differ signiﬁcantly in gender, nationality,
or any variable in the questionnaire (p > 0.05). Those who declined
blood sampling were younger (<10 years of age, 6.2% vs. 2.5%, p =
0.03) and less likely to have a sibling participating in the study
(1.7% vs. 6.4%, p = 0.01).
Although all 699 questionnaires were completed, 2–8% of the
answers were incomplete. BCG administration was reported in 79%
(477/601), prior positive TST in 0.47% (3/639), and prior positive
Table 2
Patients with a positive IGRA
LTBI Previous TB
Patient 1 Patient 2 Patient 3 Patient 4
Gender Male Female Female Male
Age, years 5 18 18 14
Emirati + + + +
Received BCG at birth + + + +
Had previous positive TST    +
Had previous positive IGRA    
Previously treated for TB    +
IGRA reading 0.67 0.77 0.77 2.06
Risk factors
Household contact from TB endemic area    +
Travel to TB endemic area    NA
Contact with TB case    
Contact with TST-positive case    
Contact with IGRA-positive case  +  
Contact with chronic cough    
Total number of risk factors 0 1 0 1
LTBI, latent tuberculosis infection; TB, tuberculosis; BCG, bacillus Calmette–Gue´rin; TST, tuberculin skin test; IGRA, interferon-gamma release assay; NA, not available.
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in 41% (254/617).
Of the 669 tested, 660 participants had a negative IGRA (99%),
four (0.6%) had a positive IGRA, two (0.3%) had an indeterminate
result (a 3.1-year-old male and a 7.2-year-old female), and one
(0.15%) participant had ineligible collection (missing mitogen tube
sample). Details of the four patients with a positive IGRA are given
in Table 2. One patient had previously been treated for TB disease.
Thus, only three LTBI cases were identiﬁed. The overall prevalence
of LTBI was 0.45% (95% CI 0.09–1.3) (Table 1). The prevalence was
0.28% (95% CI 0.07–1.5) in children <10 years of age and 0.66% (95%
CI 0.08–2.3) in older children (p = 0.4). None of the patients
reported an immune deﬁciency illness. The IGRA results had no
signiﬁcant associations with any of the risk factors elicited, neither
by the questionnaire nor by the number of risk factors per child
(p > 0.05).
According to the questionnaire, 351 (50%) participants had no
risk factors (Table 3); of these participants, 337 were tested and
two (0.6%) had LTBI. Thus, these two patients would have been
missed by the questionnaire alone.
At least one risk factor was present in 348 (50%) participants
(Table 3), of whom 330 were tested by IGRA: only one participant
(0.3%) had LTBI while 329 (99.7%) had negative results. Thus, over
99% of participants identiﬁed with at least one risk factor would
have been investigated unnecessarily.Table 3
Risk-assessment resultsa
Risk factors All respondents
(N = 699)
Household contact from TB endemic area 303/694(44%)
Travel to TB endemic area 68/684 (10%)
Contact with TB case 19/697 (3%)
Contact with TST-positive case 16/698 (2%)
Contact with IGRA-positive case 17/696 (2%)
Contact with chronic cough 51/697 (7%)








At least 1 risk factor 348 (50%)
TB, tuberculosis; TST, tuberculin skin test; IGRA, interferon-gamma release assay.
a Because of incomplete entries, the results are expressed as n/total respondents
(%) unless stated otherwise.The distribution of risk factors and LTBI patients by center are
shown in the Supplementary Material (Table S3). Interestingly,
the three LTBI patients were from Hilli center, and only 20% of the
participants in this center reported 1 TB risk factor. In Maqqam
center, 94% of the participants reported 1 TB risk factor, but no
LTBI was found (Table S3, Supplementary Material).
4. Discussion
In this study, an IGRA was used to estimate the prevalence of
pediatric LTBI in the eastern region of Abu Dhabi. The overall
prevalence of LTBI was 0.45% (95% CI 0.09–1.3). As the IGRA is
known to have lower sensitivity in young children,16 the reported
prevalence of LTBI is probably an underestimate.
Participants over 10 years of age had an LTBI prevalence of
0.66% (95% CI 0.08–2.3). This value is lower than the 8% found in a
recent study involving medical students in UAE,3 suggesting TB
exposure increases with age.
The use of questionnaires to assess the risk of TB exposure is not
implemented in the UAE. In a diverse population from the
Northern California Region, children 0–18 years of age who
received routine TST as part of universal screening were assessed
for TB risk factors. The prevalence of a positive TST was 1.0%. Risk
factors associated with a positive TST included a history of
receiving the BCG vaccine (odds ratio 2.31, 95% CI 1.70–3.13) and a
household member with a positive TST or TB disease (odds ratio
1.53, 95% CI 1.14–2.04).4 The authors suggested a ﬁve-item risk
assessment questionnaire that accurately identiﬁed risk factors
associated with LTBI in US children; the items were: child received
BCG vaccine, household member with a history of TB, child born
outside the USA, child lived outside the USA, and household
member born outside the USA.4
This study showed that for each 169 participants with no risk
factor on the questionnaire, one (0.6%) would have LTBI. In
addition, for each 330 participants with at least one risk factor on
the questionnaire, one (0.3%) would have LTBI. The performance of
the questionnaire in our community would, therefore, lead to a few
missed LTBI cases and numerous unnecessary investigations.
However, regional variations may have an impact on these
estimations (Table S3, Supplementary Material). Therefore,
implementing screening policies requires careful assessment of
the TB prevalence in the region.
This study had limitations. The recruitment of participants from
outpatient clinics (instead of schoolchildren, for example) invoked a
selection bias. The responses to the risk assessment questionnaire
were not veriﬁed by a single observer (e.g., unsure of prior BCG or
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the participants were Emiratis, and LTBI occurred exclusively among
them. This selection was due to the health insurance for Emiratis,
which covered AHS visits where the IGRA was offered. Most
expatriates attend other clinics. The performances of the question-
naire and of the IGRA were not compared to the TST, as BCG
vaccination is offered to all children born in the UAE.
Two important ﬁndings were identiﬁed in this study. First,
using the IGRA, the estimated prevalence of LTBI in the studied
pediatric population was 0.45% (95% CI 0.09–1.3). Second, 44% of
the participants had a household contact from a TB endemic area,
10% had traveled to a TB endemic area, and 3% had had contact
with a TB case. Thus, based on risk factor assessment, half of the
UAE pediatric patients are eligible for TB screening, although most
(99.7%) will not have LTBI.
The relatively low prevalence of LTBI (0.45%) perhaps reﬂects
protection offered by residence visa screening, BCG vaccination at
birth, or other undetermined variables. Further studies are
required before implementing the IGRA as a screening tool in
the UAE pediatric population, including investigations in other
regions of the country (urban and rural) and studying the cost-
effectiveness of the IGRA.
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